Corneal collagen crosslinking (CXL) is a minimally invasive treatment that can stabilize corneal ectatic disorders including keratoconus, pellucid marginal degeneration, or postrefractive surgery ectasia. The benefits of CXL have been well documented. New research is focused on modifying current treatment protocols with the goals of maximizing corneal stability while also shortening overall procedure time.

中文翻译：

---

角膜胶原交联治疗扩张的最新进展。

角膜胶原交联 (CXL) 是一种微创治疗方法，可以稳定角膜扩张疾病，包括圆锥角膜、透明边缘变性或屈光手术后扩张。CXL 的好处已得到充分证明。新的研究重点是修改当前的治疗方案，以最大限度地提高角膜稳定性，同时缩短总体手术时间。